Bolt Biotherapeutics, Inc. 8-K

What Happened
Bolt Biotherapeutics, Inc. announced its financial results for the quarter and full year ended December 31, 2025 and provided a business update via a press release dated March 12, 2026. The company furnished that press release as Exhibit 99.1 to an 8‑K filed on March 12, 2026.

Key Details

• Press release dated March 12, 2026 reports Q4 and full‑year 2025 results and a business update (Exhibit 99.1).
• The results cover the period ended December 31, 2025.
• The information was furnished (not “filed”) under Item 2.02 and expressly is not subject to certain liability protections under the Exchange Act or incorporated by reference.
• The 8‑K was signed by William P. Quinn, President, Chief Executive Officer and Chief Financial Officer.

Why It Matters
This 8‑K signals Bolt’s official public release of its latest earnings and operational update. Retail investors should review the Exhibit 99.1 press release for specific financial metrics (revenue, net loss/gain, cash runway) and any commentary on clinical, regulatory, or corporate milestones that could affect near‑term valuation or funding needs. Because the release was furnished rather than filed, investors should read the press release itself and any subsequent filings (e.g., Form 10‑Q/10‑K) for the formal, detailed financial statements and disclosures.